PMID- 37740072
OWN - NLM
STAT- MEDLINE
DCOM- 20230925
LR  - 20231122
IS  - 1550-7416 (Electronic)
IS  - 1550-7416 (Linking)
VI  - 25
IP  - 6
DP  - 2023 Sep 22
TI  - Fabrication and Characterization of Antibody-Loaded Cationic Porous PLGA 
      Microparticles for Sustained Antibody Release.
PG  - 92
LID - 10.1208/s12248-023-00859-6 [doi]
AB  - Poly lactic-co-glycolic acid (PLGA) microparticles have been formulated to allow 
      the sustained release of numerous drugs, including antibodies. It is well-known 
      that antibodies are susceptible to chemical and physical stress; therefore, it is 
      necessary to be loaded on PLGA microparticles under mild conditions. In the 
      present study, we constructed cationic porous PLGA microparticles that could be 
      electrostatically adsorbed with infliximab as a model antibody. Cationic porous 
      PLGA microparticles were prepared using the double emulsion method by adding 
      polyethyleneimine and ammonium bicarbonate. After antibody loading, surface pores 
      closure was achieved by mild heating. The size of the optimized formulation was 
      approximately 5 mum, exhibiting a positive charge. The loaded antibody was 
      gradually released from the formulation over 56 days. Based on a tumor necrosis 
      factor (TNF)-alpha inhibition assay, the released infliximab maintained its 
      pharmacological activity. Collectively, we successfully loaded antibodies into 
      PLGA microparticles while maintaining activity and demonstrating long-acting 
      properties.
CI  - (c) 2023. The Author(s), under exclusive licence to American Association of 
      Pharmaceutical Scientists.
FAU - Hanaki, Ayaka
AU  - Hanaki A
AD  - Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, 
      Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, 
      Japan.
FAU - Ogawa, Koki
AU  - Ogawa K
AD  - Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, 
      Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, 
      Japan.
FAU - Tagami, Tatsuaki
AU  - Tagami T
AD  - Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, 
      Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, 
      Japan.
FAU - Ozeki, Tetsuya
AU  - Ozeki T
AD  - Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, 
      Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, 
      Japan. ozekit@phar.nagoya-cu.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230922
PL  - United States
TA  - AAPS J
JT  - The AAPS journal
JID - 101223209
RN  - 0 (Glycols)
RN  - B72HH48FLU (Infliximab)
RN  - 0 (Antibodies)
SB  - IM
MH  - *Glycols
MH  - Infliximab
MH  - Porosity
MH  - *Antibodies
MH  - Biological Assay
OTO - NOTNLM
OT  - Poly lactic-co-glycolic acid (PLGA)
OT  - antibody
OT  - controlled release
OT  - microparticles
EDAT- 2023/09/23 11:42
MHDA- 2023/09/25 06:42
CRDT- 2023/09/22 23:28
PHST- 2023/05/21 00:00 [received]
PHST- 2023/08/30 00:00 [accepted]
PHST- 2023/09/25 06:42 [medline]
PHST- 2023/09/23 11:42 [pubmed]
PHST- 2023/09/22 23:28 [entrez]
AID - 10.1208/s12248-023-00859-6 [pii]
AID - 10.1208/s12248-023-00859-6 [doi]
PST - epublish
SO  - AAPS J. 2023 Sep 22;25(6):92. doi: 10.1208/s12248-023-00859-6.